Where Tech Meets Bio

Where Tech Meets Bio

Home
Weekly Highlights
Deep Dives
Features
About

March 2026

Weekly Tech+Bio Highlights #79: A Pharma Factory in an Egg
Lilly's $2.75B generative chemistry deal and why AI research might be locked into 'hypernormal' science
 • Roman Kasianov and Andrii Buvailo, PhD
Weekly Tech+Bio Highlights #78: AI Agents Rush In
Roche and Lilly scale up pharma's biggest AI supercomputers, a billion-dollar startup unveils its virtual cell, and agents are everywhere
 • Roman Kasianov, Andrii Buvailo, PhD, and BiopharmaTrend
Weekly Tech+Bio Highlights #77: AI-Guided mRNA Vaccine Shrinks Dog's Cancer
Google's AI doctor passes its first clinic test, China's first take-home BCI, OpenFold3 goes fully open, and arXiv is going independent
 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD
Simulating the Control Arm: Virtual Patients at the Trial Bottleneck
Digital twins promise smaller, faster trials, and the regulatory scaffolding is forming. But there’s still a validation gap.
 • BiopharmaTrend
Weekly Tech+Bio Highlights #76: Neurons, Genomes, and Self-Driving Labs
Living neurons play DOOM, Lilly uses digital twins to scale GLP-1 production, generative genomics are now in Nature, and a rice-grain-sized retinal…
 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD
The €25B vs €219B Problem: Europe's Plan to Fix Biotech
Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.
 • BiopharmaTrend
Weekly Tech+Bio Highlights #75: Lilly's Supercomputer, FDA's One-Trial Shift, and China Deals Get Pricey
Generate:Bio's $400M IPO, federated ADMET modeling across five pharma companies, Gilead's $7.8B CAR-T buyout, and an $80M AI-enabled brain health clinic…
 • BiopharmaTrend and Roman Kasianov

February 2026

© 2026 BiopharmaTrend (BPT Analytics Ltd) · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture